Targeting the HOX/PBX dimer in breast cancer

Breast Cancer Research and Treatment

Volumn 136, Issue 2, 2012, Pages 389-398

  Morgan, Richard ^a   Boxall, Angie ^a   Harrington, Kevin J ^b   Simpson, Guy R ^a   Gillett, Cheryl ^c   Michael, Agnieszka ^a   Pandha, Hardev S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; HOX; HXR9; MCF7; PBX; SKBR3

Indexed keywords

ANTINEOPLASTIC AGENT; PBX PROTEIN; PEPTIDE CXR9; PEPTIDE HXR9; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DIMERIZATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GENE INTERACTION; GENE REPRESSION; GENETIC ASSOCIATION; HOX GENE; HOXB1 GENE; HOXB2 GENE; HOXB3 GENE; HOXB4 GENE; HOXB5 GENE; HOXB6 GENE; HOXB7 GENE; HOXB8 GENE; HOXB9 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULARLY TARGETED THERAPY; ONCOGENE; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, FOS; GENES, P53; HOMEODOMAIN PROTEINS; HUMANS; MAMMARY GLANDS, HUMAN; MICE; PEPTIDES; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868204679     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2259-2     Document Type: Article

References (33)

1. Abramovich C, Humphries RK (2005) Hox regulation of normal and leukemic hematopoietic stem cells. Curr Opin Hematol 12(3):210-216
2. Iimura T, Pourquie O (2007) Hox genes in time and space during vertebrate body formation. Dev Growth Differ 49(4):265-275
3. Moens CB, Selleri L (2006) Hox cofactors in vertebrate development. Dev Biol 291(2):193-206
4. Hoegg S, Meyer A (2005) Hox clusters as models for vertebrate genome evolution. Trends Genet 21(8):421-424
5. Scott MP (1993) A rational nomenclature for vertebrate homeobox (HOX) genes. Nucleic Acids Res 21(8):1687-1688
6. Shah N, Sukumar S (2010) The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10(5):361-371
7. Chen H, Zhang H, Lee J, Liang X, Wu X, Zhu T, Lo PK, Zhang X, Sukumar S (2007) HOXA5 acts directly downstream of retinoic acid receptor beta and contributes to retinoic acid-induced apoptosis and growth inhibition. Cancer Res 67(17):8007-8013
8. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S (2000) Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405(6789):974-978
9. Care A, Silvani A, Meccia E, Mattia G, Peschle C, Colombo MP (1998) Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. Oncogene 16(25):3285-3289
10. Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS, Argani P, Sukumar S (2006) HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 66(19):9527-9534
11. Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G et al (2012) The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci USA 109 (8):2736-2741
12. Galant R, Walsh CM, Carroll SB (2002) Hox repression of a target gene: Extradenticle-independent, additive action through multiple monomer binding sites. Development 129(13):3115-3126
13. Di-Poi N, Koch U, Radtke F, Duboule D (2010) Additive and global functions of HoxA cluster genes in mesoderm derivatives. Dev Biol 341(2):488-498
14. Lappin TR, Grier DG, Thompson A, Halliday HL (2006) HOX genes: Seductive science, mysterious mechanisms. Ulster Med J 75(1):23-31
15. Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS (2007) Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res 67(12):5806-5813
16. Shears L, Plowright L, Harrington K, Pandha HS, Morgan R (2008) Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol 180(5):2196-2201
17. Plowright L, Harrington KJ, Pandha HS, Morgan R (2009) HOX transcription factors are potential therapeutic targets in nonsmall-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer 100(3):470-475
18. Daniels TR, Neacato II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML (2010) Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia 24(9):1555-1565
19. Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS (2010) Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer 10:89
20. Phelan ML, Sadoul R, Featherstone MS (1994) Functional differences between HOX proteins conferred by two residues in the homeodomain N-terminal arm. Mol Cell Biol 14(8):5066-5075
21. Piper DE, Batchelor AH, Chang CP, Cleary ML, Wolberger C (1999) Structure of a HoxB1-Pbx1 heterodimer bound to DNA: Role of the hexapeptide and a fourth homeodomain helix in complex formation. Cell 96(4):587-597
22. Knoepfler PS, Calvo KR, Chen H, Antonarakis SE, Kamps MP (1997) Meis1 and pKnox1 bind DNA cooperatively with Pbx1 utilizing an interaction surface disrupted in oncoprotein E2a-Pbx1. Proc Natl Acad Sci USA 94(26):14553-14558
23. Morgan R, In der Rieden P, Hooiveld MH, Durston AJ (2000) Identifying HOX paralog groups by the PBX-binding region. Trends Genet 16(2):66-67
24. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC et al (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Animal 22(3):195-201
25. White RA, Aspland SE, Brookman JJ, Clayton L, Sproat G (2000) The design and analysis of a homeotic response element. Mech Dev 91(1-2):217-226
26. Cailleau R, Young R, Olive M, Reeves WJ Jr (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53(3): 661-674
27. Cheng W, Liu J, Yoshida H, Rosen D, Naora H (2005) Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11(5):531-537
28. Gendronneau G, Lemieux M, Morneau M, Paradis J, Tetu B, Frenette N, Aubin J, Jeannotte L (2010) Influence of Hoxa5 on p53 tumorigenic outcome in mice. Am J Pathol 176(2):995-1005
29. Yokota I, Sasaki Y, Kashima L, Idogawa M, Tokino T (2010) Identification and characterization of early growth response 2, a zinc-finger transcription factor, as a p53-regulated proapoptotic gene. Int J Oncol 37(6):1407-1416
30. Wang H, Mo P, Ren S, Yan C (2010) Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. J Biol Chem 285(17):13201-13210
31. Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Minna JD, Fujisawa T, Gazdar AF (2007) Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers. Ann Surg Oncol 14(4):1397-1404
32. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450(7170):741-744
33. Chen H, Lee JS, Liang X, Zhang H, Zhu T, Zhang Z, Taylor ME, Zahnow C, Feigenbaum L, Rein A et al (2008) Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res 68(10): 3637-3644